Navigation Links
Icahn School of Medicine at Mount Sinai awarded $2.7 million from NIH to investigate novel therapy for eczema
Date:11/25/2013

The National Institutes of Health has awarded a research team at the Icahn School of Medicine at Mount Sinai $2.7 million to study systemic treatments for patients with moderate to severe atopic dermatitis (AD), also known as eczema. Currently, no treatments are available that achieve long-term remission without difficult side effects for this debilitating skin disorder, characterized by inflammation, severe itching, and a rash that can adversely affect many aspects of everyday life.

The team will investigate the efficacy of a new intravenous medication, ILV-094, which blocks IL-22, an important protein that has been shown in animal models to trigger epidermal growth and differentiation abnormalities and chronic inflammation, which are major features of AD. The researchers see the study as potentially groundbreaking in using "narrow pathway"-targeted immune interventions for not just AD, but other "allergic" inflammatory diseases of the skin or other organs, such as asthma.

At the Icahn School of Medicine at Mount Sinai, Emma Guttman, MD, PhD, Associate Professor of Dermatology, and Director of the Laboratory for Inflammatory Skin Diseases, and Mark Lebwohl, MD, Professor and Chair of Dermatology, will lead the study. James G. Krueger, MD, PhD, D. Martin Carter Professor and head of the Laboratory for Investigative Dermatology at The Rockefeller University, will oversee the mechanistic studies for the trial. Dr. Guttman has a joint appointment at Rockefeller and will conduct clinical and mechanistic studies at both institutions.

Dr. Guttman was the first investigator to show in humans that a separate population of T cells secrete interleukin 22 (IL-22) and she also discovered the importance of the Th22 pathway and IL-22 in AD.

"Dr. Guttman has been at the forefront of many of the most important strides in understanding the pathophysiology of atopic dermatitis," said Dr. Lebwohl. "This trial is an important step in developing safer treatments for patients with moderate to severe AD."

"I hope that this research results in a final proof of concept and a novel treatment for AD without side effects," said Dr. Guttman. The clinical trial is expected to last five years. The majority of the clinical trial, will be conducted at the Icahn School of Medicine at Mount Sinai.


'/>"/>

Contact: Mount Sinai Press Office
newsmedia@mssm.edu
212-241-9200
The Mount Sinai Hospital / Mount Sinai School of Medicine
Source:Eurekalert

Related medicine news :

1. Icahn School of Medicine at Mount Sinai Honors Innovators in Scientific Research and Health Care Philanthropy at 2013 Commencement Ceremony
2. Icahn School of Medicine at Mount Sinai and Bene Pharmachem Gmbh to Collaborate on Clinical Studies for Mucopolysaccaridoses
3. Icahn School of Medicine at Mount Sinai and Rensselaer Polytechnic Institute Announce Academic Collaboration
4. Icahn School of Medicine at Mount Sinai Grants Exclusive License to Cellular Dynamics International for Development of a Cellular Therapy for Cardiac Muscles
5. World-Renowned Gastroenterologist Jean-Frédéric Colombel, MD, Joins the Icahn School of Medicine at Mount Sinai
6. Janina A. Longtine, MD of the Icahn School of Medicine at Mount Sinai Elected President of the Association for Molecular Pathology
7. A Best Manuscript Award Goes to the Cardiovascular Research Center at Icahn School of Medicine at Mount Sinai
8. A Best Manuscript Award goes to Icahn School of Medicine at Mount Sinai
9. Four Researchers from Icahn School of Medicine at Mount Sinai Among the 400 Most Highly Influential Biomedical Researchers in the World
10. Even Preschoolers View the Overweight Negatively
11. Catastrophic Head Injuries to High School Football Players Rising
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/1/2020)... , ... April 01, 2020 , ... ... private of information under California law,” says Keller Grover LLP attorney Eric A. ... notice of data breaches and the negligent release and disclosure of medical information ...
(Date:3/28/2020)... ... March 27, 2020 , ... With social distancing, or more ... the day, people of all ages are challenged to find different ways to ... in the best of times—the physical distance mandated to prevent the pandemic’s spread ...
(Date:3/28/2020)... ... March 28, 2020 , ... iPatientCare, ... practice management, and patient engagement solutions has expanded the availability of telehealth services ... time of crisis, telemedicine has a big role in fighting coronavirus . ...
(Date:3/27/2020)... ... March 27, 2020 , ... NeoTract, a wholly owned ... of urology, today announced that Harpreet Wadhwa, M.D., East Valley Urology Center in ... recognizes that Dr. Wadhwa has achieved a high level of training and experience ...
(Date:3/22/2020)... ... March 21, 2020 , ... ... solutions that hospitals, medical organizations, and health centers can use for patient care ... coronavirus pandemic, many medical professionals are working around the clock to implement emergency ...
Breaking Medicine News(10 mins):
(Date:4/2/2020)... (PRWEB) , ... April 02, 2020 , ... ... Clinical Research Participation (CISCRP) will be initiating the 2nd annual Medical Hero Appreci-a-thon ... all “Medical Heroes” – medical and healthcare professionals, researchers and study volunteers. ...
(Date:4/1/2020)... ... April 01, 2020 , ... ... leading provider of urgent care and accessible primary care, launches its telemedicine platform, ... nationwide healthcare clinics will now provide virtual visits, allowing our medical providers to ...
(Date:3/30/2020)... MOBILE, Ala. (PRWEB) , ... March 30, 2020 ... ... solutions company, is launching a new solution, TalkWithYourDoc.com . By leveraging ... solution enables providers of all sizes to continue offering revenue-generating healthcare services while ...
Breaking Medicine Technology: